RECRUITINGOBSERVATIONAL
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
About This Trial
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Who May Be Eligible (Plain English)
Who May Qualify:
\-
Who Should NOT Join This Trial:
- patients with a known hypersensitivity to components of AJOVY
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
\-
Exclusion Criteria:
* patients with a known hypersensitivity to components of AJOVY
Treatments Being Tested
DRUG
Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
Locations (1)
Pharmacovigilance Department
Osaka, Japan